Probi (STO:PROB) has signed a distribution agreement with Impexia, a pharmaceutical sales and marketing company well established in the Turkish market. Impexia plans to launch Probi Digestis® during Q3, 2014.
Turkey is a fast moving economy and has a growing probiotic market with several new players successfully launching new probiotic products lately. The market is expanding and new brands are growing as the medical community is increasing its appreciation for probiotics.
“Impexia is committed to gain market share in the years to come” said Peter Nählstedt, CEO of Probi. “Impexia is a strong Partner of Probi’s with good market access to key geografical areas in Turkey having high potential for Probi Digestis. Probi Digestishas a large number of positive clinical studies within gut health.”
Probi Digestis is based on Lactobacillus plantarum 299v, which targets bloating, gas formation and pain, common symptoms that are sometimes mild or temporary but often more severe and causing a low quality of life for people suffering from such symptoms.
“Probi Digestis will be launched under the Probi brand in Turkey to emphasize the high quality probiotic ingredient, invented and further developed by Probi,” said Tayfun Kapcioglu, chief operating officer of Impexia. “Probi Digestis will be sold via Impexia’s field force targeting GPs and gastroenterologists and the large number of pharmacies available in the Turkish market.”
“Probi is looking forward to entering the Turkish market and we will be supporting this key launch through high involvement in the marketing activities,” said Nählstedt. “We are very much looking forward to a productive cooperation with Impexia in Turkey.”
The information is such that Probi AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.